You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.
-
Administrative Supplement to restore fee funds
SBC: AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC. Topic: NINDSProject Summary Traumatic brain injuryTBIcauses detrimental behavioral dysfunctions and brain neurodegeneration butunfortunatelythere currently is no effective pharmaceutical TBI treatmentThe underlying PhaseSTTR grant is to develop a new class of TBI drugs that inhibit the protease cathepsin BGenetically deleting the cathepsin B gene in mice results in substantial behavioral and pathology improve ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
An epitope focused nanoparticle vaccine for MRSA and biodefense
SBC: VLP BIOTECH, INC. Topic: NIAIDDESCRIPTION provided by applicant Overall Staphylococcus aureus is a gram positive bacteria which possesses a multitude of virulence factors It is a frequent and severe pathogen in hospitals and of increasing concern in the community where it results in severe skin infections pneumonia bacterial endocarditis and sepsis A significant proportion of these infections are the result of methici ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
An innovative WGS platform for discovery, annotation, and interpretation of all forms of human genetic variation.
SBC: Base2 Genomics LLC Topic: 172PROJECT SUMMARY Modern DNA sequencing technologies have transformed our ability to interrogate human genomes in a single experimentthereby eliminating the inherent blind spots of gene panels and whole exome sequencingFurthermorerecent speed and economy improvements are driving the cost of whole genome sequencingWGSdown to that of WESthereforewe foresee a transition over the next two years to WGS a ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
An integrative multi phenotype pipeline for drug evaluation pharmacogenomics and attribute prediction
SBC: PHENVOGEN LLC Topic: 300PROJECT SUMMARY The process of drug discovery is costly and many promising compounds fail during clinical trials By then expenses upward of $ million dollars per failed drug may have incurred and these financial risks hamper research efforts and ultimately reduce the availability of treatment options In this research proposal we are using systematic approaches to map the relationships be ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
A novel anti gonorrhea immunotherapeutic
SBC: Planet Biotechnology Incorporated Topic: NIAIDAntimicrobial resistance is a major public health problem worldwide Neisseria gonorrhoeae Ng the causative agent of the sexually transmitted infection gonorrhea has become multidrug resistant and has achieved superbug status Novel therapeutics against Ng are urgently needed Complement C is a key arm of innate immune defenses A mechanism used by several pathogens including Ng to esca ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
A Novel Therapeutic that Harnesses MIcrotubules to Enhance Corneal Wound Healing Following an Alkaline Burn
SBC: MicroCures Inc. Topic: NEIThe cornea is one of the most important tissues in the eye and its transparency is critical for good visual function in humansCorneal tissue injuries are the most common everyday issue for practicing ophthalmologists and can run the gamut in severityIn severe modelssuch as corneal alkaline burnsextensive healing is needed and often the burn victim is left with reduced visual acuityHealing of large ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
A Transparent Surgical Mask to Improve Patient Caregiver Communication Minimize Errors and Increase Patient Satisfaction
SBC: FaceView Mask, LLC Topic: 600PROJECT SUMMARY Hearing loss innate and acquired occurs in over million Americans and globally in over million people To compensate many with hearing impairment rely on the combination of audio information and visual cues from the face cheeks nose and eyes to facilitate speech understanding In healthcare settings this important visual communication is severely hindered by the ubi ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
A Unified System for Wireless Optogenetics and Brain Microdialysis for Small Molecules Prototype Development and Validation
SBC: AMUZA, INC Topic: 101PROJECT SUMMARY While optogenetics is well suited for understanding the dynamic activity of neural circuits the first central theme of the NIH BRAIN Initiative PAR its neurochemical impacts remain largely uncharacterized due to a lack of appropriate tools Given that the predominant mode of cellular interactions is neurochemical commercial development of such tools will fulfill the ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Automated electrophysiological analysis of neural circuitry using a novel nano electrode array for intracellular recording of membrane potential
SBC: CYION TECHNOLOGIES LLC Topic: 101Summary Nervous systems process information by integrating the electrical activity of neurons in complex networks The alterations in the flow of electrical activity through neuronal networks of the brain play a causal role in the pathogenesis and or the appearance of symptoms of neurodegenerative and psychiatric diseases A fundamental goal of BRAIN Initiative is therefore to elucidate how the ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Automated Electrophysiology Assessment of Drug induced Cardiotoxicity Based on Parallel Noninvasive Nanoelectrode Array
SBC: CYION TECHNOLOGIES LLC Topic: NIBIBSummary Drug safety issues pose a serious challenge to the health and well being of patients The development of our innovative technology aims to address a significant gap in the in vitro assessment of drug induced cardiotoxicity which is the number one reason for withdrawals of all marketed drugs as well as the premature termination of promising drug development candidates Pressured by the eno ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health